Missouri Judge Approves Bayer 7.25 Billion Dollar Roundup Settlement
A Missouri judge has approved Bayer’s 7.25 billion dollar settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could finally resolve litigation that has weighed on the German company for close to a decade.
Payouts of Up to 165,000 Dollars
St. Louis Circuit Judge Timothy Boyer found the settlement fair, reasonable and adequate, and said the average individual payouts were fair and adequate in a written judgment. People who were exposed to Roundup and developed non-Hodgkin lymphoma, a form of blood cancer, will receive payments ranging from 10,000 to 165,000 dollars, depending on how they used the product, their age when diagnosed and the severity of their illness. Residential users such as home gardeners and occupational users such as landscapers are both covered, with payments weighted by the length and intensity of exposure. The settlement also covers people who are diagnosed in future years.
Monsanto, the Bayer unit behind the product, will make declining capped annual payments into a special fund for up to 21 years, totalling as much as 7.25 billion dollars including sums already paid. Payments will decline over time under the capped schedule agreed by the parties. The approved settlement includes 600 million dollars for attorneys’ fees, and the court’s order is subject to appeal, according to reports.
A Decisive Milestone for Bayer
Bayer chief executive Bill Anderson called the approval a decisive milestone in the company’s strategy to contain the Roundup litigation, which covers thousands of claims from users who say the company should have warned them that the weedkiller could cause lymphoma. The case was filed in St. Louis, home to Bayer’s North America crop science division and the state where many of the lawsuits were brought.
The settlement follows a United States Supreme Court ruling in June in the Durnell case, which found that federal pesticide law overrides state failure to warn claims, a decision Judge Boyer cited in approving the deal. Claimants will be able to seek payment through a long term claims programme, with two groups covered: people already diagnosed and people diagnosed during a 16 year period after final approval. For Bayer, the agreement offers a path to put a long and costly chapter behind it, while for claimants it promises a structured claims programme that will pay out over the coming two decades.

